WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory Challenges
Cerrar esta carpetaEssential Medicines
Ver el documentoTreating 3 million people living with HIV/AIDS by 2005
Ver el documentoAIDS medicines and diagnostics service
Ver el documentoFixed-dose combination therapy
Ver el documentoHIV antiretrovirals and diagnostics funding
Ver el documentoWorld Bank ARV procurement manual
Ver el documentoResearch on new HIV microbicides
Abrir esta carpeta y ver su contenidoSafety and Efficacy Issues
Abrir esta carpeta y ver su contenidoVaccines and Biomedicines
Abrir esta carpeta y ver su contenidoHerbal Medicines
Abrir esta carpeta y ver su contenidoRegulatory and Safety Action
Abrir esta carpeta y ver su contenidoConsultation Document
Ver el documentoProposed International Nonproprietary Names: List 90
Ver el documentoRecommended International Nonproprietary Names: List 51
 

Research on new HIV microbicides

New antiviral agents are being developed by scientists and HIV experts from the UK Medical Research Council (MRC) and the Department for International Development (DFID). The antiviral properties of potential microbicides could work in a number of ways. They could kill or otherwise immobilize the virus, create a barrier to block infection, or prevent the infection from taking hold after it has entered the body. An effective microbicide would combine these mechanisms.

A large-scale trial is planned to evaluate the effectiveness of two of the six vaginal microbicides that are now in the final stages of clinical development. Updates on recent international microbicide research and development, including information on the first Phase III trials, will be released shortly.

Microbicides are likely to be of particular benefit to women who are increasingly bearing the brunt of the HIV epidemic and now account for over 50 per cent of people newly infected with HIV. Microbicides could potentially control the risk of contracting HIV and other sexually transmitted diseases.

Reference: http://www.mrc.ac.uk

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012